1800 244 735

Helpline (02) 9874 9777

Therapeutics conference videos now online

HDBuzz covered CHDI’s therapeutics conference in February 2011 from Palm Springs. Now, videos of many of the scientific presentations have been made available to watch online.

The therapeutics conference

The annual Huntington’s disease Therapeutics Conference, hosted by CHDI Foundation Inc., is a unique forum for HD researchers to come together, share exciting findings, and establish collaborations and partnerships that accelerate the pace of research into therapies for Huntington’s disease.

CHDI is a not-for-profit ‘virtual biotechnology company’ that aims to “rapidly discover and develop drugs that delay or slow Huntington’s Disease”. It’s the largest single driving force behind the development HD treatments.

Shortly after HDBuzz launched in January, we reported from the 2011 Therapeutics Conference, held in Palm Springs, California. Our daily reports from the conference gave a plain-language overview of all the main science presented at the conference – and it was a ton of exciting stuff!

You can find our reports by searching for ‘CHDI’ on HDBuzz.net.

The videos

For the first time, videos of many of the scientific presentations have now been made available online. To find them, visit http://chdifoundation.org/ and click the ‘Presentations from the 2011 HD Therapeutics Conference’ link.

Be prepared, though: these presentations were delivered by scientists, to a room full of scientists – so they’re all rather more intensive than a typical HDBuzz article!

So, you might find helpful to consult our daily conference reports, alongside the videos.

We applaud this move – it was an exciting conference and the science deserves to reach as many people as possible. As far as HDBuzz is concerned, making conference presentations available online like this is a great step forward.

Latest Research Articles

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Published date: 31 August, 2022

We’re back for day 2 at @hdfcures! This morning’s talks will be focused on clinical trial planning and therapeutic updates from clinical studies. The sheer number of talks related to human trials compared to previous years is so encouraging! Updating metrics for clinical trials A better system for disease categorization The first talk of this ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 1

Published date: 31 August, 2022

Hello and welcome from the HDBuzz team who are currently at the Hereditary Disease Foundation (@hdfcures) 2022 Milton Wexler Biennial Symposium in Boston! It’s the dawn of an exciting new era for HDBuzz. Due to our new partnership with @hdfcures, we are now able to live tweet many of the talks from this meeting which ... Read more

Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials

Published date: 29 August, 2022

Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by uniQure in June suggested AMT-130 was safe and well tolerated in the small group of people that were treated with a low dose of the drug. Now we’re back to ... Read more